Evaluating Intracranial Response with DXd ADCs & Other Biologics: Lessons Learned & Opportunities Ahead

• Traditionally, large molecules including ADCs are thought to have no intracranial efficacy due to inability to cross the blood brain barrier
• Presenting evidence of intracranial efficacy of multiple DXd ADCs and mAbs, challenging this dogma
• Explaining this information can be utilised to address the unmet needs for patients with brain metastases

Speakers:

David Leung

Head of Imaging

Daiichi Sankyo